Symbols

HRMY

Harmony·NASDAQ

--(--)

HRMY fundamentals

HRMY Q4 2025 Earnings

Harmony (HRMY) released its earnings on Feb 24, 2026: revenue was 243.78M (YoY +21.12%), beat estimates; EPS was 0.38 (YoY -55.29%), missed estimates.

Revenue / YoY

243.78M

+21.12%

EPS / YoY

0.38

-55.29%

Report date

Feb 24, 2026

HRMY Earnings Call Summary for Q4,2025

Blockbuster Achievement: WAKIX set to reach $1 billion in 2026, with Q4 2025 revenue up 21% YoY to $243.8 million.
Pediatric Expansion: FDA approval for pediatric cataplexy (≥6 years) adds 5% of narcolepsy market, with teams prepped for rapid uptake.
IP Defense Success: 6/7 generic filers settled, delaying potential generic entry to March 2030 (if pediatric exclusivity granted).
Pipeline Momentum: Pitolisant GR NDA submission in Q2 2026, and new CNS formulation for fatigue with 2042 patent protection.
Financial Resilience: $882.5 million cash balance supports R&D and commercial expansion, with no debt.

Earnings

EPS

Revenue

Revenue & Expenses

HRMY has released its 2025 Q4 earnings report, with revenue of 243.78M, reflecting a YoY change of 21.12%, and net profit of 22.49M, showing a YoY change of -54.55%. The Sankey diagram below clearly presents HRMY's revenue sources and cost distribution.

Key Indicators

Harmony (HRMY) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Harmony (HRMY)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Harmony (HRMY)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Harmony (HRMY)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown